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Abstract
Deep brain stimulation (DBS) is an effective treatment for Parkinson’s disease (PD) patients with motor fluctuations and 
dyskinesias. The key DBS efficacy studies were performed in PD patients with unknown genotypes; however, given the 
estimated monogenic mutation prevalence of approximately 5–10%, most commonly LRRK2, PRKN, PINK1 and SNCA, 
and risk-increasing genetic factors such as GBA, proper characterization is becoming increasingly relevant. We performed 
a systematic review of 46 studies that reported DBS effects in 221 genetic PD patients. The results suggest that monogenic 
PD patients have variable DBS benefit depending on the mutated gene. Outcome appears excellent in patients with the most 
common LRRK2 mutation, p.G2019S, and good in patients with PRKN mutations but poor in patients with the more rare 
LRRK2 p.R1441G mutation. The overall benefit of DBS in SNCA, GBA and LRRK2 p.T2031S mutations may be compro-
mised due to rapid progression of cognitive and neuropsychiatric symptoms. In the presence of other mutations, the motor 
changes in DBS-treated monogenic PD patients appear comparable to those of the general PD population.
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Introduction
Deep brain stimulation (DBS) provides symptomatic motor 
benefit for patients with advanced Parkinson’s disease (PD) 
[1–4]. The benefit of symptom control through DBS sur-
passes that of optimal medical treatment in patients with 
motor fluctuations and dyskinesias, and it is a relatively safe 
treatment option for motor complications of idiopathic PD 
[1–5]. DBS is often performed in relatively early-onset PD, a 
population in which it has been estimated that at least 5–10% 
of cases are not sporadic, but may carry genetic mutations 
[6, 7]. Genetic cases often are phenotypically different com-
pared to sporadic patients, and this factor may influence 
clinical outcome [6, 8].
Though DBS has demonstrated efficacy, randomized 
studies have been performed in PD patients without genetic 
characterization raising questions of suitability of various 
monogenic forms and their relevance in DBS outcome. It 
is known that medication effects may vary between differ-
ent mutations. For example, patients with PRKN mutations 
generally are particularly prone to levodopa-induced dys-
kinesias, whereas patients with LRRK2 mutations tend to 
show a normal sustained benefit for levodopa [8–11]. The 
effects of other antiparkinsonian drugs, such as rasagiline, 
may also be modulated by the genotype [12]. Given the 
variability in medication effects, it is conceivable that there 
are also differences in the treatment response to DBS in 
advanced monogenic PD. There are several case reports and 
small case series of DBS outcomes in patients with genetic 
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PD, but due to a lack of information synthesis, we performed 
a systematic review on the effects of DBS in genetic PD.
Methods
Search strategy
The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement was followed [13]. We 
performed a PubMed search from inception to June 26, 2018 
with keywords “deep brain stimulation or DBS”, “Parkin-
son’s or Parkinson or Parkinsonism” and “genetic or gene or 
GBA or PRKN or PARKIN or LRRK2 or SNCA or PINK1 
or VPS35 or DJ-1 or UCHL1 or GIGYF2 or HTRA2 or 
TMEM230 or CHCHD2 or RIC3 or ATP13A2 or PLA2G6 
or FBX07 or SYNJ1 or VPS13C or DNAJC6”. All original 
English language articles concerning genetic PD patients 
treated with DBS were included. Animal studies and review 
articles were excluded.
The initial search identified 220 articles, and we included 
an additional 16 relevant studies found in the manual search 
of reference lists (Fig. 1). All abstracts of these studies were 
screened, and 184 studies were excluded in the first round 
(no monogenic PD patients or not treated with DBS n = 64, 
review or commentary article n = 92, animal study n = 28). 
The remaining 52 studies were assessed fully for eligibility 
and six more studies were excluded in the second round 
(genetic test negative n = 2, no genetic testing n = 1, review 
or commentary article n = 3). Finally, 46 studies of these 
Fig. 1  Flow chart of study 
inclusion and exclusion
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236 studies met all selection criteria and were included in 
the systematic review (Table 1). A summary of the included 
studies is presented in Table 2. The included studies reported 
221 genetic PD patients who were treated with DBS. How-
ever, two studies reported partially the same patients [14, 
15].
Specific aims
This review of evidence aimed to systematically investigate 
DBS outcome in monogenic PD compared to the general 
PD population. The primary aim was to evaluate the motor 
benefit of the DBS operation in each monogenic PD type. 
An additional aim was to evaluate effects on non-motor 
symptoms, including possible cognitive and neuropsychi-
atric symptoms.
Selection criteria
Search terms and the PubMed search were planned by 
two authors (T.K. and V.K.). All titles and abstracts were 
reviewed by one investigator (T.K.). Studies were excluded 
if the title and/or abstract were not suitable for the aim of 
the review. Full texts were obtained for appropriate studies 
or if the relevance of an article was uncertain. The inclusion 
criteria for the selected studies were as follows: (1) a human 
study, (2) genetic PD patients treated with DBS, and (3) 
English language. The data extracted from each study were 
study year, first author’s family name, number of patients, 
mutated gene, specific mutation, patient age at disease onset 
and DBS implantation, target nucleus of DBS, more spe-
cific lead positioning, pre- and postoperative UPDRS-III 
scores, follow-up time and outcome (Table 1). UPDRS-III 
scores of control cohort’s (mutation non-carriers, NC) are 
also reported in Table 1 if the information was available. In 
the outcome evaluation, an improvement of 30% or more 
in the UPDRS-III motor score was considered to indicate 
favourable outcome; 20–30%, moderate outcome; and 
< 20%, poor/mild outcome [58–60].
Quality control
The quality of the included studies was evaluated according 
to the Newcastle-Ottawa Scale (NOS) [61]. NOS includes 
selection, comparability, and exposure or outcome. The 
scale ranged from 0 to 11 stars, with the highest rating rep-
resenting the greatest quality. Six months or more was a 
limit for the adequate follow-up time. Pre- and postoperative 
evaluation was thought to be accomplished if the outcome 
was reported properly with percentage improvement of the 
UPDRS-III score or verbally. A total score of 0–3 was con-
sidered to indicate to poor quality; 4–7, moderate quality; 
and 8–11, good quality. The NOS total score is presented in 
Table 1 and the scale is presented more accurately in Sup-
plementary Table 1. A summary of the assessed quality of 
the studies is presented in Supplementary Table 2.
Results
A summary of the primary results is presented in Table 2. 
Altogether, 46 studies and 221 monogenic PD patients 
treated with DBS were included in the systematic review 
(Table 1).
LRRK2
Seventeen studies [9, 15–30] reported 87 patients (target: 
subthalamic nucleus (STN) n = 79, not available (NA) n = 8). 
The outcome was reported in 73 patients (83.9% of patients); 
with percentage improvement of the UPDRS-III score in 49 
patients and verbally in 24 patients. The motor outcome was 
mostly favourable in patients with LRRK2 mutation. Only 
five studies with ten patients reported poor/mild/moderate 
outcomes. Both patients with the p.T2031S (c.6091A > T) 
mutation (n = 2) developed neuropsychiatric problems 
5–7 years after implantation. The outcome appeared poor in 
patients with p.R1441G (c.4321C > G) mutations whereas it 
appeared excellent in patients with p.G2019S (c.6055G > A) 
mutations.
PRKN
Eighteen studies [11, 15, 16, 19, 21, 31–43] reported 67 
patients (STN n = 51, globus pallidus interna (GPi) n = 5, 
zona incerta n = 1, NA n = 10). The outcome was reported 
in 57 patients (85.1%); UPDRS-III percentage improve-
ment was reported  in 45 patients and the outcome was 
described verbally in 12 patients. Fifty-one patients (76.1%) 
had favourable long-term motor outcomes. Six patients in 
three different studies were reported to have modest or poor 
outcomes.
GBA
Five studies [14, 15, 19, 44, 45] reported 50 patients (STN 
n = 33, GPi n = 4, ventral intermediate nucleus (VIM) 
n = 1, NA n = 12). Samples partially consisted of same 
patients in two studies [14, 15]. The outcome was reported 
in 30 patients (60.0%); UPDRS-III percentage improve-
ment in 28 patients and the outcome was described ver-
bally in 2 patients. Eighteen patients were reported to have 
favourable, three patients moderate and nine patients poor 
long-term motor outcomes. One study reported better out-
comes with STN-DBS and VIM-DBS than with GPi-DBS 
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[15]. GBA mutation carriers developed cognitive impair-
ment faster than patients without mutations.
SNCA
Five patients were reported in five case reports [46–50] 
(STN n = 4, GPi n = 1). The motor outcome was favourable 
for all patients in the short-term but 3/5 patients developed 
cognitive and/or neuropsychiatric problems a few years after 
implantation. The percentage change in the UPDRS-III score 
was documented in two patients.
VPS35
Four studies [51–54] reported five patients (STN n = 3, NA 
n = 2). Favourable motor outcome was reported in four cases 
and minor motor benefit complicated by dysarthria in one 
case. The percentage change in the UPDRS-III score was 
reported in three patients.
PINK1
Five case reports [21, 32, 38, 55, 56] including one patient in 
each report (STN n = 4, GPi n = 1) were reported. Favourable 
motor outcome was observed in three patients and moder-
ate outcome in one case. One patient developed imbalance, 
gait impairment, dysarthria, and behavioral changes after 
operation and mental deterioration was documented a few 
years later.
Exclusion of poorer quality studies
Unfortunately, many studies (Table 1) lacked important 
information as shown in the Supplementary Table 1. Poorer 
quality studies have tendency for bias; therefore, in the Sup-
plementary Table 3, data are presented after exclusion of 
poorer quality studies such as studies lacking the informa-
tion about DBS target, pre- and postoperative evaluation, 
adequate follow-up time or outcome information. Further-
more, as Lythe et al. [14] and Angeli et al. [15] reported 
partly the same patients, we tested the conclusions also 
when the smaller study was excluded. Nevertheless, after the 
Table 2  Summary of key findings according to the mutated gene
STN subthalamic nucleus, GPi globus pallidus interna, VIM ventral intermediate nucleus, NA not available
a One patient had also PRKN mutation and one had GBA mutation
b One patient had both PRKN and PINK1 mutations
c Two studies reported partially same patients, but it was not possible to separate individual patients that were reported twice. One patient had 
also LRRK2 mutation and one had PRKN mutation
Gene Studies (n) Patients (n) Target Outcome
LRRK2 17 87a STN: n = 79 (90.8%)
NA: n = 8 (9.2%)
Mostly favourable motor outcome. Four studies with eight patients 
(9.2%) reported poor motor outcomes and one study reported moder-
ate outcomes for two patients. Both patients with the LRRK2 p.T2031S 
(c.6091A > T) mutation (n = 2) developed neuropsychiatric problems 
5–7 years after implantation. The outcome appears poor in patients with 
LRRK2 p.R1441G (c.4321C > G) mutations (n = 5), whereas it appears 
excellent in patients with LRRK2 p.G2019S (c.6055G > A) mutations
PRKN 18 67b STN: n = 51 (76.1%)
GPi: n = 5 (7.5%)
Zona incerta: n = 1 (1.5%)
NA: n = 10 (14.9%)
Fifty-one patients (76.1%) had favourable long-term motor outcomes. Four 
patients (6.0%) were reported to have modest outcome in two different 
studies and one study with two patients (3.0%) reported poor benefit
GBA 5 50c STN: n = 33 (66.0%)
GPi: n = 4 (8.0%)
VIM: n = 1 (2.0%)
NA: n = 12 (24.0%)
Eighteen patients were reported to have favourable, three patients moderate 
and 9 patients poor long-term motor outcomes. One study reported better 
outcomes with STN-DBS and VIM-DBS than with GPi-DBS. GBA muta-
tion carriers developed cognitive impairment faster than patients without 
mutations
SNCA 5 5 STN: n = 4 (80.0%)
GPi: n = 1 (20.0%)
Favourable motor outcome but three of five patients developed cognitive or 
neuropsychiatric problems a few years after implantation
VPS35 4 5 STN: n = 3 (60.0%)
NA: n = 2 (40.0%)
Favourable motor outcome in four cases and minor motor benefit compli-
cated by dysarthria in one case
PINK1 5 5b STN: n = 4 (80.0%)
GPi: n = 1 (20.0%)
Favourable motor outcome in three cases and moderate in one case
22q11.2.Del. 
Syndrome
1 3 STN: n = 1 (33.3%)
GPi: n = 2 (66.6%)
Favourable motor outcome
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exclusion of these studies, the results remained essentially 
the same (Supplementary Table 4).
Discussion
We report the following key findings: (1) DBS outcome 
appears excellent in patients with LRRK2 p.G2019S 
(c.6055G > A) mutations, good in patients with PRKN 
mutations and poor in patients with LRRK2 p.R1441G 
(c.4321C > G) mutations, (2) the overall benefit of DBS 
in SNCA, GBA and LRRK2 p.T2031S (c.6091A > T) muta-
tions may be decreased due to rapid progression of cog-
nitive and neuropsychiatric symptoms, and (3) in other 
mutations, the motor outcome in DBS-treated genetic PD 
patients appears generally comparable to that of sporadic 
PD patients.
A recent smaller review of 30 studies described the 
effects of DBS mainly in patients with LRRK2, PRKN and 
GBA mutations [62]. In the present PRISMA-compliant 
systematic review of 46 studies and 221 patients, the 
most comprehensive data were available for patients with 
LRRK2 and PRKN mutations. The combined evidence sug-
gests that patients with LRRK2 mutations generally have a 
good response to DBS, and patients with the most common 
LRRK2 mutation, the p.G2019S mutation [7], may even 
have better outcome than the general PD population. How-
ever, the reported LRRK2 cases of p.R114G, p.T2031S and 
p.N1437H (c.4309A > C) mutation carriers appeared to 
have less favourable outcome. This interpretation is lim-
ited by the small number of reported DBS-treated cases of 
rarer LRRK2 mutations. For the PRKN mutations, the lit-
erature supports a view that patients with PRKN mutations 
are optimal candidates for DBS.
Apart from the LRRK2 and PRKN genes, the published 
literature concerning individual monogenic mutations and 
DBS is less comprehensive and the data are clearly limited 
with respect to both the number of patients and duration 
of follow-up. The available data are limited to five DBS-
treated patients with VPS35 mutation, and the patients 
have shown favourable sustained motor outcome in 4/5 
cases. The available literature also suggests that most 
patients with mutations in GBA tend to achieve favour-
able long-term motor outcome from STN-DBS. Despite 
good motor outcome, GBA mutation carriers may develop 
cognitive impairment after DBS faster than patients with-
out mutations. SNCA patients commonly develop cogni-
tive and neuropsychiatric problems [8]. The literature sup-
ported a good motor outcome after DBS also in patients 
with SNCA mutations; however, 3/5 patients developed 
cognitive and neuropsychiatric problems a few years after 
DBS implantation. Indeed, the non-motor features of 
genetic PD may be a limiting factor in the overall benefit 
of DBS in some mutations, such as SNCA and LRRK2 
p.T2031S. While the motor benefit from DBS may initially 
be clear, the rapid non-motor progression may lessen the 
sum value for the quality of life. A recent study in SNCA 
A53T mutated rodents suggested that DBS may be neuro-
protective [63]. Nonetheless, in human PD patients with 
SNCA mutations, the neuropsychiatric progression appears 
to be rapid despite DBS. The issue could be the level of 
damage at the time of implantation, and earlier DBS in 
these patients might possibly provide different outcomes.
Preoperative response to levodopa is the best single 
predictor of the postoperative outcome of DBS [64]. This 
indicator appears useful also in patients with monogenic 
mutations and the response was reported in practically all 
included studies. Another relevant predictor is the locali-
zation of DBS electrodes [65]. Unfortunately, there were 
studies, which did not report DBS targets and most stud-
ies lacked information about lead positioning. As the lit-
erature expands in the future, the effect of targets and lead 
positioning should be investigated in more detail. In most 
studies, STN was preferred over GPi as the target. Hence it 
remains ambiguous whether there are any relevant differ-
ences of clinical outcome between STN and GPi stimula-
tion in monogenic PD. One study reported also a patient 
with VIM stimulation which is an unusual target for PD 
patients because VIM stimulation improves only tremor, not 
other PD symptoms [66, 67]. Finally, it is important to note 
that the genetic status may have a positive as well as a nega-
tive influence on outcome of surgery and this issue should be 
taken into consideration in the interpretation of DBS studies. 
For example, the EARLYSTIM trial was performed with 
young-onset PD patients [5] and there could have been an 
overrepresentation of PRKN patients in the sample.
In conclusion, monogenic PD patients have variable DBS 
outcomes depending on the mutated gene. Most patients 
benefit from STN-DBS, at least in the short-term; however, 
the current evidence does not support or is questionable for 
DBS implantation for patients with p.T2031S or p.R114G 
mutations in the LRRK2 gene or mutations in the SNCA or 
GBA genes. The best outcome from DBS surgery appears to 
be in patients with LRRK2 p.G2019S or PRKN mutations.
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